HAART has been associated with a dramatic decrease in mortality caused by HIV infection, but it has complicated clinical management of HIV-infected individuals, which now must include the treatment of an array of chronic diseases. The impact of coinfection with hepatitis C virus (HCV) is a focus of particular concern [1] .
The prevalence of HCV coinfection in HIV-infected individuals is high, ranging from 10% to 40%, and it can be up to 80% in highly exposed cohorts [2] [3] [4] [5] . This high rate of coinfection is likely associated with shared transmission routes, particularly injection drug use and the receipt of blood products or transfusions. The long latency period prior to HCV disease may account for the lack of considerable liver disease in HIV-infected individuals before the introduction of HAART. With improvements in treatment and therapy, HCV infection will continue to be a serious and highly prevalent disease in these longer-living individuals.
Numerous studies document the negative effects of HIV coinfection on the course of HCV disease [6] [7] [8] [9] [10] . The effect of HCV coinfection on HIV disease progression has been extensively investigated, although study findings differ widely in both the magnitude and nature of the reported associations. Several studies have found significantly increased rates of progression to death or of AIDS-defining events in HCV-coinfected patients [4, [11] [12] [13] [14] [15] [16] , whereas others have found no such effect [6] [7] [8] [9] [10] [17] [18] [19] [20] .
The present study is an extension of an earlier evaluation of the same cohort (the HIV Atlanta VA Cohort Study [HAVACS] ), which found no association between HCV coinfection and clinical progression of HIV disease [3] . The previous HAVACS study, like many earlier studies, primarily used data from the pre-HAART era [21] [22] [23] [24] . We speculated that many factors, including the hepatotoxicity of HAART regimens and increased survival durations for patients receiving this therapy, may yield different findings [25] [26] [27] [28] [29] .
METHODS

Study population.
The study population consisted of all HIVinfected patients who were tested for HCV infection at the Atlanta Veterans Affairs Medical Center (Georgia) since 1992 and who were seen from January 1997 through October 2001. HAART became available in this cohort in mid-1996. This retrospective, clinic-based cohort study included clinical and demographic information collected from January 1982 through October 2001.
HCV infection status was determined using a secondgeneration EIA. Eighty-eight percent of all patients were tested for HCV antibody during the study period, and a patient was considered to be HCV infected from the date of a positive test result forward. A minority of patients ( ) had HCV RNA n p 58 levels determined, and 91% of these tests yielded positive results. History of hepatitis B virus (HBV) infection was defined as a positive test result either for hepatitis B surface antigen or for antibody to surface antigen. CD4 + cell counts and HIV load data were extracted for 3 time points: within 6 months of HCV test date, 6 months after HAART was started, and at the last visit before October 2001. CD4 + cell counts were measured by standard 3-color flow cytometry using FACscan (Becton Dickinson), and HIV-RNA loads were determined by PCR (Amplicor RT-PCR).
Date of AIDS diagnosis was defined as the date the patient's condition met either the 1987 or 1993 Centers for Disease Control and Prevention (CDC) definition of AIDS [30] [31] [32] . Antiretroviral (ARV) use was categorized as: (1) HAART for у1 month, (2) history of use of ARVs but not use of HAART, and (3) no history of ARV therapy or of receipt of HAART for !1 month.
The patient's risk factor for HIV infection, race, and age at the time of HCV testing were included in the analysis. The risk factor was defined as injection drug use, compared with other risk factors, and race was defined as black versus white race, with Hispanic ethnicity classified as black or white race as appropriate. No other race groups were represented.
Statistical analyses. Statistical analysis was performed using SAS software, version 8 (SAS Institute). Bivariate analyses evaluated the distribution of each covariate by HCV infection status, with Mantel-Haenszel ORs and associated P values calculated. Kaplan-Meier curves and multivariate survival models were created for the 3 time periods considered: (1) the time from diagnosis of HIV infection to death, (2) the time from AIDS diagnosis to death, and (3) the time from diagnosis of HIV infection to that of AIDS diagnosis. Each multivariate model contained the same covariates, except that the first model (time from diagnosis of HIV infection to death) included an additional variable for AIDS diagnosis. Interaction variables for HCV infection status with clinically relevant factors were inserted and then removed by backwards elimination. Adjusted survival curves (by HCV infection status) were derived for each final model.
Logistic regression models for immunological progression. Ordinal logistic regression models were constructed for the change in CD4 + cell count from time of HAART initiation to 6 months after initiation (i.e., the short-term effect) and to date of last CD4 + cell count (i.e., the long-term effect). The covariates included were HCV infection status, CD4
+ cell count at the time of initiation of HAART, risk factor for HIV infection, history of HBV infection, age at date of testing for HCV infection, and time between measurements (for the long-term model only).
RESULTS
Cohort characteristics.
A total of 970 subjects were eligible for inclusion in the study. The prevalence of HCV infection in the cohort was 31.6%. A total of 73.1% of patients were receiving HAART at some point during follow-up, and 66.6% had AIDS diagnosed. Being a man who has sex with men (MSM) was the most prevalent risk factor for HIV infection (48.0%); 22.4% of subjects had injection drug use listed as the primary risk factor. The cohort was predominantly black (73.2%), with a median age of 41.7 years at the date of HCV testing.
HCV-infected patients were more likely to be older, to be of black race, to be intravenous drug users, and to have never received HAART ( for all) (table 1). They were less P ! .0001 likely to have tested positive for hepatitis B antigen (P p .043). HCV-infected and HCV-uninfected patients experienced similar recoveries in the CD4 + cell count after initiating HAART (both for those who received short-term HAART and those who received long-term HAART). The HIV load was not found to be significantly different at date of HCV testing. Furthermore, because CD4 + cell counts were more routinely determined in this population and were found to be highly colinear with HIV load, HIV load data were not incorporated into any multivariate models.
Multivariate survival analyses. HIV-HCV-coinfected patients experienced shorter durations of survival from the date of diagnosis of HIV infection than did HIV-infected/HCVuninfected patients (hazard ratio [HR], 2.47; 95% CI, 1.26-4.82) (table 2 and figure 1 ). The use of HAART was independently associated with an improved duration of survival (HR, . Patients coinfected with HCV and HBV had better survival durations (borderline significance). Although HBV-infected persons were less likely to be injection drug users overall, there was no difference in the frequency of injection drug use between HCV-infected/HBV-uninfected individuals and HCV-HBVcoinfected individuals.
HIV-HCV-coinfected patients also experienced significantly decreased durations of survival from the time of AIDS diagnosis (HR, 1.84; 95% CI, 1.09-3.10) (table 2 and figure 2 ). The use of HAART improved survival duration (HR, 0.26; 95% CI, 0.16-0.42), whereas a CD4 + cell count of !50 cells/mm 3 at the time of HCV testing was associated with a decreased survival duration (HR, 3.39; 95% CI, 2.15-5.35). There was no difference between HCV-infected and HCV-uninfected individuals with regard to risk to progression to AIDS from HIV diagnosis (data not shown).
Immunological response to HAART. HCV infection was not associated with an altered CD4 + cell response to HAART (data not shown). All patients experienced a similar recovery in the CD4 + cell count 6 months after initiation of HAART, regardless of HCV infection status, although injection drug use was independently associated with a decreased CD4 + cell count 
recovery. The long-term model that considered CD4
+ cell count recovery from initiation of HAART to time of the last visit also found no difference.
DISCUSSION
This study addresses the impact of HIV-HCV coinfection on the progression of HIV disease and presents 4 clinically relevant findings. First, the prevalence of HCV coinfection (31.6%) in this cohort is high and is in accordance with the previous HAVACS study [3] . Second, coinfected patients were less likely to have received HAART than were HCV-uninfected patients. Third, coinfection with HCV results in a significantly decreased duration of survival from the times of diagnoses of HIV infection and AIDS. Fourth, HCV coinfection does not affect short-term or long-term recovery of the CD4 + cell count associated with HAART.
These findings demonstrate a shift in the effect of HCV coinfection from the pre-HAART era to the HAART era. A previous evaluation of survival in the HAVACS cohort found that HCV infection had no effect on progression of HIV infection, as did several other longitudinal studies that included data from prior to 1997 [3, 11, 17, 21, 22] . Our present findings are supported by other large studies conducted in the HAART era, notably the Swiss Cohort Study, which observed decreased durations of survival from initiation of HAART in HIV-HCVcoinfected patients [4, [12] [13] [14] [15] [16] . In contrast to Greub et al. [4] , however, our data suggest that this difference in the durations of survival is not attributable to a compromised CD4 + cell response to treatment. Other recent studies have found no effect of HCV coinfection on survival [18, 20, 24, 33] ; Sulkowski et al. [18] , for example, reported no significant difference in survival from time of entry into the cohort. It is unclear why the reported impact of HCV coinfection continues to vary, although cohort differences and variability in the time intervals employed for modeling may be important factors.
Possible reasons for the observed difference between the pre-HAART era and the HAART era include the following: (1) the observed decrease in the duration of survival is because of the introduction of HAART and treatment-associated hepatotoxicity; (2) a larger proportion of patients were tested for HCV in the HAART era, correcting a selection bias (88% vs. 53% previously); and (3) a longer duration of follow-up time allowed for the development of significant hepatic disease. The latter is unlikely, because there was no significant change in mortality rates for liver disease after 1997 (D.R., unpublished data).
This study has several strengths. The HAVACS cohort is large ( ) and includes a long follow-up period, and routine n p 970 HCV testing has been done since 1992. Patients who use the Atlanta Veterans Affairs Medical Center's services receive the majority of their care within the system, decreasing the number of losses to follow-up and standardizing clinical data. Finally, the use of date of AIDS diagnosis-a clinically defined time point-as a starting point for survival analysis adds strength to these findings.
One limitation of this study may be its lack of generalizability, because the HAVACS cohort consists of veterans who are primarily black and male. The subset of patients coinfected with HCV is further distinguished from the general population, because they are more likely than HIV-infected/HCV-uninfected patients to be injection drug users. The growing epidemic of HIV-HCV coinfection in the developing world is primarily at-tributable to injection drug use, however, and we believe that this cohort provides an accurate reflection of current demographic and clinical trends regarding this dual infection. This study is also limited by the unavailability of important data regarding liver disease, including HCV genotype, alcohol use, and clinical data, such as aspartate aminotransferase and alanine aminotransferase levels, which were not routinely and reliably available for most patients [34] [35] [36] [37] [38] . However, only 20 patients had liver disease-related deaths in this period (5 HCVuninfected patients and 15 HCV-infected patients). Although efforts were made to control for important confounders, it is possible that some variables remain unavoidably biased. The patient's risk factor for HIV infection was self-reported, and injection drug users may be less likely than others to report their risk factor. It is possible that the 1-month cutoff for dichotomized HAART use disguises differences in the duration of and adherence to HAART therapy between HCV-infected and HCV-uninfected individuals, which could also be linked to a decrease in the survival duration. The median duration of HAART use was slightly lower for HCV-infected patients than for HCV-uninfected patients (593 vs. 741 days), but the causality of this difference cannot be determined; it may be that the decreased survival of HCV-infected patients is driving the decreased use of HAART, or vice versa.
The nature of clinical progression in HIV-HCV-coinfected individuals must be better understood, such that safe and effective treatment and preventive measures may be employed. Although HIV-HCV-coinfected patients were less likely than those infected only with HIV to receive HAART, their CD4 + cell count recovery with treatment was as strong as that observed for HCVuninfected patients. This suggests that HIV-HCV-coinfected patients may be treated successfully for HIV infection. The high prevalence of HCV coinfection in this cohort and the accelerated progression to death underscore the importance of this secondary infection, now and into the future.
